Abstract
Angiosarcoma is a rare, devastating malignancy with few curative options for disseminated disease. We analyzed a recently published genomic data set of 48 angiosarcomas and noticed recurrent amplifications of HOXA cluster genes in 33% of patients. HOXA genes are master regulators of embryonic vascular development and adult neovascularization, which provides a molecular rationale to suspect that amplified HOXA genes act as oncogenes in angiosarcoma. HOXA amplifications typically affected multiple pro-angiogenic HOXA genes and co-occurred with amplifications of CD36 and KDR, whereas the overall mutation rate in these tumors was relatively low. HOXA amplifications were found most commonly in angiosarcomas located in the breast, and were rare in angiosarcomas arising in sun-exposed areas on the head, neck, face and scalp. Our data suggest that HOXA amplified angiosarcoma is a distinct molecular subgroup. Efforts to develop therapies targeting oncogenic HOX gene expression in AML and other sarcomas may have relevance for HOXA amplified angiosarcoma.
Introduction
Angiosarcoma is a rare malignancy with a poor prognosis. The 5-year survival rates are about 30% with conventional approaches, and survival is almost entirely dependent on surgical resection of low-stage disease 1,2.
Due to the low incidence of angiosarcoma, large genomic studies have been challenging. One of the largest cohort reported to date includes 48 samples from 36 patients who underwent comprehensive genomic profiling of archived tumor samples 3. This study reported substantial heterogeneity in the mutational landscape of angiosarcoma related to location. Tumors from sun exposed sited (head, neck, face and scalp – HNFS) showed a pattern of high mutational burden that was associated with sensitivity to checkpoint blockade in 2 patients. The study also confirmed common alterations of the p53 and Ras pathways, consistent with previous reports 1,4-6, as well as a known risk of angiosarcoma in Li Fraumeni patients. The combination of p53 mutations and RAS pathway alterations in angiosarcoma was modelled in recent independent studies, and these tumors may be sensitive to mTOR or Ras pathway inhibition 6-9. Finally, the study by Painter et al 3 identified recurrent mutations in PIK3CA that are likely activating, supplying a molecular rationale for PI3Kα inhibition as a potential therapeutic strategy for these patients. Other studies identified recurrent mutations in MAPK signaling, PTPRB, PLCG1, KDM6A and amplification of FLT4 and MYC 4,5,10-12.
We reanalyzed the data from the study by Painter and colleagues 3 available in cBioPortal 13,14 in order to determine if additional subsets could be identified that might have potential therapeutic implications. We noticed an unexpectedly high frequency of HOXA cluster alterations. The HOX genes are a set of 39 evolutionary conserved transcription factors that are arranged in 4 clusters (HOXA, HOXB, HOXC and HOXD) and determine body patterning during embryogenesis (Figure 1A) (reviewed in 15). Paralogues within the different clusters exhibit a certain degree of functional redundancy, and in the right context, they can be swapped with only minor phenotypic consequences. The HOXA cluster in particular plays a role in the emergence of the blood forming and vascular systems, which arise from a common embryonic progenitor 15,16. Postnatally, the later HOXA cluster genes (HOXA7-13) are expressed and required for the maintenance and growth of hematopoietic stem and uncommitted progenitor cells. Individual HOXA genes also play a role in regulating the emergence of endothelial progenitor cells (EPCs) from the bone marrow, neovascularization and wound healing 15. This suggest a potential mechanism for HOXA amplifications to act as an oncogene in angiosarcoma. In this study, we report the molecular and clinical features of HOXA amplified angiosarcomas in the patient cohort reported by Painter and colleagues 3.
Methodology
Previously published and openly available data from the AngioSarcoma Project data were retrieved and analyzed directly in cBioPortal based on Painter et al 2020 3. HOXA cluster gene copy number alterations were inferred using ReCapSeg as detailed by Painter et al 2020 3. Clinical annotation data of AngioSarcoma patients was also obtained from cBioPortal. Integrative genome viewer (IGV) tracks of the HOXA cluster in all 48 samples in Figure 1C use the cBioPortal default settings, but patients were ordered by HOXA sequence abundance.
Significance testing for HOXA gene enrichment analyses used Fisher’s exact test implemented in R (version 3.5). Significance was tested bot on a sample level and a patient level, and results were similar for both. The more stringent patient level analysis is shown. Bonferroni correction method as implemented in R (p.adjust() function) was applied to correct for multiple testing.
Data availability
all data is available at cBioPortal: http://www.cbioportal.org/study/summary?id=angs_project_painter_2018#summary
Results
Overall, amplification of at least one pro-angiogenic HOXA cluster gene was present in 12/36 (33%) patients. The most frequently amplified HOXA cluster gene with a documented role in vasculogenesis/angiogenesis was HOXA3. HOXA9, HOXA11 and HOXA13 were significantly co-amplified with HOXA3 as part of a larger amplification (Figure 1 B). In 4 patients, the amplification occurred within the HOXA cluster encompassing a minimal region including HOXA3-HOXA9.
HOXA amplification was significantly associated with amplifications of the vascular endothelial marker CD36 (p=5.59E-4, remaining significant after Bonferroni correction at 1.62E-2), and KDR (p=1.07E-3, remaining significant after Bonferroni correction at 3.11E-21) (Table 1). KDR encodes the VEGFR2, and KDR mutation/amplification has previously been identified by other groups 3,10,11. Overall, HOXA amplified tumors had a comparatively low mutation burden, although the difference failed to reach statistical significance (Figure 1C, Table 1).
The percent of co-occurring signaling pathway mutations (PIK3CA, MAP3K13, NF1, NRAS, HRAS, BRAF, RAF1) was not substantially different from non-HOXA amplified samples. Ras pathway mutations occur with similar frequencies in HOXA cluster dysregulated AML, where they are usually subclonal. Finally, p53 alterations were also similar between the two groups (Table 1).
We did not observe any statistically significant differences in the clinic presentation of HOXA cluster amplified angiosarcomas compared to those without HOXA amplification, although several interesting trends may warrant further study. We observed a trend toward less frequent location in the sun exposed HNFS area compared to the whole cohort (17 vs 33% in those with and without HOXA amplification, respectively), and more frequent location in the breast (67 vs 46%). There was also a trend towards a lower percentage of male patients with HOXA amplifications (male: 17 vs 33%). We observed a non-significant trend towards a higher proportion of patients receiving tumor-directed therapy at the time of sample submission (58 vs 42%), which could be a surrogate for higher stage disease linked to worse outcomes. However, reliable outcomes data for this cohort were not available. Based on the available clinical annotation in cBioPortal, only 2 patients with HOXA amplified angiosarcoma had prior radiation. This seems somewhat low based on clinical experience of breast angiosarcomas as secondary malignancies after irradiation for breast cancer, but is not significantly different from the entire cohort (17 vs 21%). HOXA amplified samples had the same age distribution, with two peaks, one around age 30, and a second peak around age 65 (Table 1).
Discussion
Here, we report a not previously recognized, high percentage of HOXA amplifications in angiosarcoma. Dysregulation of HOXA cluster genes is a common feature of acute myeloid leukemia (AML). Distinct HOXA cluster genes also play critical roles in regulating bone marrow derived endothelial precursor cells (EPC) and in situ neovascularization 15. Specifically, HOXA3 and HOXA9 are the two key angiogenic/vasculogenic homeobox transcription factors during development and in wound healing 17-25. Furthermore, HOXA11 is expressed in vascular smooth muscle cells in fetal, but not adult tissue 26. HOXA genes are separated into two distinct groups, the anterior (HOXA1-5) and posterior (HOXA 7-13) cluster. All HOX-genes within each group are regulated coordinately in muscle development (controlled by the anterior HOXA cluster) and hematopoiesis (controlled by the posterior HOXA cluster). In contrast, individual HOXA genes within the anterior HOXA cluster have opposing functions in angiogenesis: HOXA3 is a key pro-angiogenic transcription factor and not expressed in adult quiescent vascular endothelium. Conversely, its close neighbor HOXA5 is highly expressed in quiescent endothelium, and HOXA5 expressing endothelial cells fail to respond to angiogenic stimuli 27,28. In addition, HOXD10 expression has been shown to inhibit angiogenesis 15,29.
We propose here that HOXA amplifications act as an oncogene in angiosarcoma. This is supported by the following observations: HOXA amplification are common in angiosarcoma. Several of the amplified HOXA genes have well described roles in in driving blood vessel growth, suggesting a molecular mechanism for how HOXA amplifications could induce aberrant vascular proliferation. Finally, a subset of patients, the amplified domain did not encompass the entire HOXA cluster, but there was consist focal amplification of a segment that included pro-angiogenic members of the HOXA cluster (HOXA3-9), further supporting this notion.
Further characterization of HOXA amplified angiosarcoma samples revealed that these tumors constitute a defined molecular subgroup. HOXA amplified tumors exhibit a pattern of additional genomic alterations that is different from non-HOXA amplified tumors, including a strong association with amplification of KDR and CD36, as well as a trend towards lower mutational burden.
Our finding suggest that HOXA amplified angiosarcomas may have a different etiology from the more common angiosarcomas of the head, neck, face and scalp 2. The latter carry a mutational signature that is consistent with UV induced DNA damage 3. In contrast, HOXA amplified angiosarcomas may be caused by the amplification of developmental master regulators of vasculogenesis and angiogenesis. The observed trend of different presentation (deeper tumors, commonly in the breast versus sun-exposed areas), and a distinct genomic landscape support the notion of a different origin.
Finally, our study raises the possibility that therapies developed to modulate HOX-cluster expression in other malignancies could have efficacy in this subtype of angiosarcoma. Regulators of HOXA transcription in other malignancies include Menin 30 and DOT1L 31-33. Menin inhibitors in particular have reported pre-clinical efficacy in AML, Ewing sarcoma 34 and hepatocellular carcinomas 35, and are currently in clinical trials. Direct small molecule inhibitors of HOX transcription factors are also an active area of research. Our findings support further studies to confirm HOXA amplifications in additional patient cohorts, and determine whether HOX gene expression is required for tumor growth and can be targeted for therapeutic purposes.
Data Availability
Data availability: all data is available at cBioPortal: http://www.cbioportal.org/study/summary?id=angs_project_painter_2018#summary
http://www.cbioportal.org/study/summary?id=angs_project_painter_2018#summary
Author contributions
KMB designed the study and wrote the manuscript. HMX conducted data analysis and statistical analysis, and co-wrote the manuscript.
Conflict of interest
The authors declare no conflict of interest.
Supplementary Table 1:
Patient clinical characteristics and recurrent amplifications/mutation of HOXA-amplified and non-HOXA amplified angiosarcomas. HOXA-amplifications were significantly associated with amplifications of KDR and CD36. There is also a non-statistically significant trend towards lower mutational burden and location in the breast versus HNSF.
Acknowledgment
We thank Nikhil Wagle for early access to results from the Count-Me-In Angiosarcoma project and helpful discussions. This work was supported by funding from the Emerson Collective Count-Me-In challenge.